Clinical Trials Browser

Breast Neoplasms × ribociclib × 90 days × Clear all

NCT06726148 2026-04-17

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Phase 1/2 Recruiting

Breast Neoplasms

NCT07174336 2026-04-17

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Phase 3 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT07400523 2026-04-17

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

Phase 3 Recruiting

Breast Neoplasms

NCT07085767 2026-04-16

OPERA-02

Phase 3 Recruiting

Breast Neoplasms

NCT04920708 2026-04-14

FAIM

Phase 2 Active not recruiting

Breast Neoplasms

NCT05238922 2026-04-14

Study of INCB123667 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT05827081 2026-04-14

Adjuvant WIDER

Phase 3 Recruiting

Breast Neoplasms, Breast Neoplasms, Male

NCT05038631 2026-04-13

Managed Access Programs for LEE011, Ribociclib

Breast Neoplasms

NCT06625775 2026-04-13

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT07164976 2026-04-13

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms

NCT07405801 2026-04-06

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT05161195 2026-04-02

Roll-over Study to Allow Continued Access to Ribociclib

Phase 4 Active not recruiting

Breast Neoplasms

NCT07340658 2026-04-02

SIE-3

Phase 3 Not yet recruiting

Breast Neoplasms

NCT01872260 2026-04-01

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT03701334 2026-04-01

NATALEE

Phase 3 Active not recruiting

5,101 enrolled 5 FDA

Breast Neoplasms

NCT04943497 2026-04-01

PROSPERITY

Breast Neoplasms

NCT06830720 2026-04-01

CAROLEEN

Breast Neoplasms

NCT06905301 2026-04-01

IMPULSE

Breast Neoplasms

NCT07054190 2026-03-31

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT07487129 2026-03-23

Clinical and P

Phase 4 Completed

Breast Neoplasms

NCT06377852 2026-03-18

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Phase 3 Recruiting

Breast Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

Breast Neoplasms

NCT05697146 2026-03-16

RosaLEE

Active not recruiting

Breast Neoplasms

NCT06930859 2026-03-16

ELEGANCE

Breast Neoplasms

NCT07237256 2026-03-16

NoLEEta

Phase 3 Recruiting

Breast Neoplasms

NCT02712723 2026-03-11

FELINE

Phase 2 Active not recruiting

121 enrolled 9 charts

Breast Neoplasms

NCT05573555 2026-03-09

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT05768139 2026-03-02

PIKALO-1

Phase 1/2 Recruiting

BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT06760637 2026-03-02

FourLight-3

Phase 3 Recruiting

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT06585969 2026-02-12

DISCORDANT

Phase 3 Withdrawn

Breast Neoplasms

NCT06757634 2026-02-05

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Phase 3 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT06797531 2026-02-04

NISLEESA

Breast Neoplasms

NCT03616587 2026-01-28

SERENA-1

Phase 1 Active not recruiting

Breast Neoplasms

NCT05996107 2026-01-28

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer

Phase 1 Recruiting

Breast Neoplasms